A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)


Rochester, Minn., Jacksonville, Fla., Phoenix/Scottsdale, Ariz.

Trial status:

Open for Enrollment

Why is this study being done?

This study is to evaluate the efficacy and safety of simtuzumab (GS-6624) in adults with idiopathic pulmonary fibrosis.

Who is eligible to participate?

Inclusion Criteria: - Male or female subjects from 45 to 85 years of age - Definite IPF within 3 years prior to screening - Be able to walk at least 50 meters Exclusion Criteria: - Significant diseases other than IPF - Obstructive lung disease - Aortic aneurysm greater than or equal to 3.5 cm in diameter - Listed as active on a lung transplant waiting list

Last updated:




IRB Number: